April 30, 2014, MOSCOW - OJSC «VEROPHARM» [RTS:VRPH, MICEX:VFRM] announces its audited financial results of the year 2013 in accordance with the International Financial Reporting Standards (IFRS).

SALES
  • Sales in 2013 amounted to RUR 5,269 mln. The share of product segments in OJSC "Veropharm" sales is as follows: Group of pharmaceutical products
    • Rx drugs sales amounted to RUR 3,725 mln. The Rx drugs sales made 70.7% of total sales of the Company against 66.8% in 2012;
    • OTC drugs sales amounted to RUR 794 mln. The OTC drugs sales made 15.1% of total sales of the Company against 14.4% in 2012;
    • Traditional drugs sales amounted to RUR 15 mln. The traditional drugs sales made 0.3% of total sales of the Company against 0.4% in 2012;
    Group of non-pharmaceutical products
    • Non-pharmaceutical products sales made RUR 735 mln, which corresponds to 14.0% of total sales of the Company.
  • Under the Federal Rembursement Program (FRP) Veropharm's sales amounted to RUR 33.8 mln according to the results of 2013, which corresponds to 0.6% of the Company's total sales.
  • The Russian Federation is the main market and ensures 94.9% of the Company's sales. During 2013 the Company has exported 5.1% of its products.
PROFIT
  • In 2013 the gross profit of OJSC "Veropharm" amounted to RUR 3,132 mln. The gross profit ratio in 2013 made 59.4%. The gross profit ratio of the segments of OJSC "Veropharm" is as stated: Group of pharmaceutical products
    • In relation to Rx drugs it made 58.4% in 2013 against 50.7% in 2012;
    • In relation to OTC drugs it made 66.2% in 2013 against 71.0% in 2012;
    • In relation to traditional products it made 46.3% in 2013 against 52.9% in 2012.
    Group of non-pharmaceutical products
    • In relation to non-pharmaceutical products it made 57.6% in 2013 against 67.0% in 2012.
  • In 2013 EBITDA amounted to RUR 1,165 mln. EBITDA margin made 22.1%.
  • Operating profit in 2013 made RUR 1,038 mln. Operating profit margin made 19.7% in 2013.
  • Net profit for the reporting period amounted to RUR 612 mln. Net profit margin made 11.6%.
FACILITIES INVESTMENTS
  • In 2013 the amount of investments assigned for modernization and equipment of the main production facilities of the Company made RUR 2,894 mln.
  • As at December 31, 2013 the debt of OJSC "Veropharm" amounted to RUR 2,667 mln, which makes no more than 30% of the Company's net assets value.

Press-release

distributed by